STAT3 and ovarian carcinoma: Thus, blocking the activation of JAK2 and STAT3 via inhibitors, siRNAs, or neutralizing IL-6 could suppress ovarian cancer cell migratory capacity, making them possible targets for future therapeutic approaches.